Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 7/20 | 0.41 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | UGCG | Q16739 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16857975 | 0.85 | MAPT (0.36) | EGLN1MEN1MAPTKMT2AMRGPRX4 | |
| SCHEMBL411012 | 0.81 | MRGPRX4 (0.52) | CTSACNR2CNR1MEN1MAPT | |
| SCHEMBL9978159 | 0.78 | CNR1 (0.42) | CTSACNR2CNR1MEN1MAPT | |
| SCHEMBL410512 | 0.77 | MRGPRX4 (0.49) | CTSACNR2CNR1MRGPRX4 | |
| SCHEMBL31267243 | 0.75 | CNR1 (0.45) | CTSACNR2CNR1MEN1MAPT | |
| SCHEMBL21634885 | 0.75 | CNR1 (0.45) | CTSACNR2CNR1MEN1MAPT | |
| SCHEMBL438387 | 0.75 | MAPT (0.45) | CTSACNR2CNR1MAPTCYP1A2 | |
| SCHEMBL412268 | 0.74 | RHOC (0.41) | CTSACNR2CNR1MAPT | |
| SCHEMBL9936769 | 0.74 | CNR1 (0.49) | CTSACNR2CNR1 | |
| SCHEMBL31267275 | 0.73 | NPC1 (0.56) | CTSAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651895-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | claimed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | claimed |
| EP-2651895-B1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | HOFFMANN LA ROCHE (CH) | 2015-07-01 | — | — | EP | disclosed |
| US-8669254-B2 | Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents | HOFFMAN-LA ROCHE INC. (US) | 2014-03-11 | — | — | US | disclosed |
| EP-2651895-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-20120157476-A1 | OXIME COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | US | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080144-A1 | OXIME COMPOUNDS AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157476-A1 | OXIME COMPOUNDS | APOB, APOL1, PON1 | CTSA 2455/4885CNR2 1642/4885CNR1 1065/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.